Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | SVP & Chief Commercial Officer | May 16, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date May 16, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,210 |
Reported balance
After 2022-05-16 transaction · row 1
1 source rowRow 1 · 2022-05-16 · Sale · Disposed 4,592 · Balance 223,210 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 01:33 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,592 | $3.95 | $18,138.40 |
DisclosureSEC source: 0001209191-22-029900 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,210 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,852 | $10.95 | $53,129.40 |
DisclosureSEC source: 0001209191-22-011437 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,802 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:24 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 67,150 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070691 · doc4.xml · derivative · entry 2 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,150 Underlying: Common Stock · 67,150 shares Expires 2029-12-15 F2 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:24 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 37,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070691 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,654 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,061 | $13.16 | $79,762.76 |
DisclosureSEC source: 0001209191-21-065221 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,854 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,192 | $13.83 | $85,635.36 |
DisclosureSEC source: 0001209191-21-052385 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,915 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,085 | $18.30 | $111,355.50 |
DisclosureSEC source: 0001209191-21-034186 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,107 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,358 | $22.37 | $343,558.46 |
DisclosureSEC source: 0001209191-21-012120 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,192 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 51,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064914 · doc4.xml · derivative · entry 2 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2028-12-17 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 28,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064914 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,550 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $19.48 | $0.00 |
DisclosureSEC source: 0001209191-19-059174 · doc4.xml · derivative · entry 2 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-12-01 F2 · derivative.exercise_date: This option vests as to 25% of the shares subject to the option on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest in equal monthly installments over the three-year period thereafter, in each case based on the Reporting Person's continuous service to the issuer. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059174 · doc4.xml · nonDerivative · entry 1 NORTHCOTT JOHN · CIK 0001615000 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · security: The grant of Restricted Stock Units ("RSUs") will vest according to a four-year vesting schedule, with 25% vesting on February 15, 2021 and the remainder vesting over three years in equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.